A Multicenter Clinical Trial of Intravesical Bacillus Calmetter-Guerin (BCG) in combination with ALT-803 in Patients with BCG Unresponsive High Grade non-Muscle Invasive Bladder Cancer

Brief description of study

The purpose of the study is to assess effectiveness and safety of the intravesical BCG (Bacillus Calmetter-Guerin) in combination with ALT-803 in patients with BCG unresponsive high-grade non-muscle invasive bladder cancer (NMIBC). During the study, we want to know how the treatment affects your body and the growth of your tumor. You will receive a urinary catheter in the bladder, combined with the drugs. ALT-803 is an investigational drug, which means that it has not been approved by the U.S FDA, but the FDA has given its permission for ALT-803 to be tested in this research study.

Clinical Study Identifier: s18-00902
ClinicalTrials.gov Identifier: NCT03022825

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.